Extended indication Extension of indication to include treatment of COVID-19 in hospitalised patients in adults and
Therapeutic value No estimate possible yet
Registration phase Registration application pending

Product

Active substance Casirivimab / imdevimab
Domain Infectious diseases
Reason of inclusion Indication extension
Main indication COVID-19
Extended indication Extension of indication to include treatment of COVID-19 in hospitalised patients in adults and adolescents aged 12 years and older weighing at least 40 kg for Ronapreve
Proprietary name Ronapreve
Manufacturer Roche
Route of administration Intravenous
Therapeutical formulation Injection
Budgetting framework Intermural (MSZ)
Additional comments Casirivimab and imdevimab have been designed to attach to the spike protein of SARS-CoV-2 at two different sites. When the active substances are attached to the spike protein, the virus is unable to enter the body’s cells.

Registration

Registration route Centralised (EMA)
Submission date February 2022
Expected Registration December 2022
Orphan drug No
Registration phase Registration application pending

Therapeutic value

Therapeutic value No estimate possible yet

Expected patient volume per year

There is currently nothing known about the expected patient volume.

Expected cost per patient per year

References medicijnkosten.nl
Additional comments Prijs incl. BTW: Ronapreve inj/infv 300mg/2,5ml (120mg/ml) 2 flac € 562,71 per stuk. Ronapreve inj/infv 1332mg/11,1ml (120mg/ml) 2 flac € 2.250,85 per stuk.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.